C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Rhea-AI Summary
C4 Therapeutics (NASDAQ: CCCC) announced that company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York.
The fireside chat is scheduled for Wednesday, February 11, 2026 at 11:30 AM ET. A live webcast will be available on the company’s Investors website, with an archived replay accessible for approximately 90 days.
Positive
- None.
Negative
- None.
Market Reaction
Following this news, CCCC has declined 7.50%, reflecting a notable negative market reaction. Our momentum scanner has triggered 3 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $1.86. This price movement has removed approximately $15M from the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
CCCC was up 6.91% while key biotech peers were mixed: SLS up 4.1%, NTHI up 1.84%, IPHA down 3.26%, TRDA down 0.42%, ELTX flat. This pattern points to stock-specific factors rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 26 | Inducement option grant | Neutral | +3.4% | Single-employee stock option inducement grant under Nasdaq Rule 5635(c)(4). |
| Jan 14 | Program milestones update | Positive | +0.9% | Outlined cemsidomide milestones, Phase 2/1b plans, and cash runway to 2028. |
| Nov 25 | Conference participation | Neutral | +0.8% | Announced fireside chat at 8th Annual Evercore Healthcare Conference. |
| Nov 06 | Q3 2025 earnings | Positive | +0.4% | Reported Q3 2025 financials, $125M equity raise, and positive cemsidomide data. |
| Oct 16 | Underwritten equity offering | Negative | +11.7% | $125M offering with shares, pre-funded and other warrants at set package prices. |
Recent CCCC news has generally seen small positive price reactions, with an underwritten offering on Oct 16, 2025 the only clear divergence, as shares rose 11.71% on potentially dilutive news.
Over the past few months, C4 Therapeutics has combined capital-raising with steady clinical and corporate updates. An underwritten offering in Oct 2025 raised $125 million, followed by Q3 2025 results with $11.2 million in revenue and detailed cemsidomide data. Strategic milestones through 2028 and an inducement option grant in Jan 2026 were also disclosed. Prior conference participation in Nov 2025 mirrors today’s Guggenheim summit appearance as part of an ongoing investor-relations cadence.
Regulatory & Risk Context
An effective S-3 shelf dated Nov 21, 2025 registers up to $400,000,000 of securities, including up to $125,000,000 of common stock under an at-the-market program. This structure provides flexible access to capital for research, development, pipeline expansion, and general corporate purposes.
Market Pulse Summary
The stock is down -7.5% following this news. A negative reaction despite routine conference participation would contrast with the generally mild positive moves seen after recent corporate and clinical updates. With the stock at 2.01, below the 2.13 200-day MA and far under the 3.72 52-week high, sentiment had already been cautious. The presence of a $400,000,000 S-3 shelf could add overhang if investors anticipate further capital raises on top of prior offerings.
AI-generated analysis. Not financial advice.
WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 taking place from February 11 – 12, 2026 in New York, NY.
Fireside Chat Details:
Date: Wednesday, February 11, 2026
Time: 11:30 AM ET
A live webcast will be available on the Investors section of the company’s website at www.c4therapeutics.com. An archived replay of the webcast will be available for approximately 90 days following the event.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
FAQ
When is C4 Therapeutics (CCCC) presenting at the Guggenheim Emerging Outlook: Biotech Summit 2026?
How can investors watch the C4 Therapeutics (CCCC) fireside chat webcast on February 11, 2026?
How long will the C4 Therapeutics (CCCC) webcast replay be available after the Guggenheim summit?
Will C4 Therapeutics (CCCC) management discuss targeted protein degradation at the Guggenheim summit?
Where and when is the Guggenheim Emerging Outlook: Biotech Summit 2026 where C4 Therapeutics (CCCC) will appear?
